

Tetsuya Kawamura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6403765/publications.pdf>

Version: 2024-02-01

54
papers

3,133
citations

516710

16
h-index

276875

41
g-index

58
all docs

58
docs citations

58
times ranked

2235
citing authors

#	ARTICLE	IF	CITATIONS
1	Literature review of allograft adenovirus nephritis and a case presenting as mass lesions in a transplanted kidney without symptoms of urinary tract infection or acute kidney injury. <i>Transplant Infectious Disease</i> , 2021, 23, e13468.	1.7	4
2	Impact of the number of steroid pulses in tonsillectomy combined with steroid pulse therapy: a nationwide retrospective study in Japan. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 19-27.	1.6	4
3	Anti-PM/ScI Antibody-positive Systemic Sclerosis Complicated by Multiple Organ Involvement. <i>Internal Medicine</i> , 2021, 60, 1101-1107.	0.7	3
4	Ratio of serum creatinine to cystatin C is related to leg strength in predialysis CKD patients. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 1079-1086.	1.6	0
5	Immunohistological score of transcription factor 21 had a positive correlation with its urinary excretion and proteinuria in immunoglobulin A nephropathy. <i>Histology and Histopathology</i> , 2021, , 18367.	0.7	2
6	Remission of proteinuria under therapeutic intervention and the renal outcomes in Japanese patients with lupus nephritis class III and IV. <i>Modern Rheumatology</i> , 2020, 30, 125-131.	1.8	1
7	Tonsillectomy Monotherapy for IgA Nephropathy: A Case Series. <i>Kidney Medicine</i> , 2020, 2, 620-628.	2.0	0
8	Transcription factor 21 expression in injured podocytes of glomerular diseases. <i>Scientific Reports</i> , 2020, 10, 11516.	3.3	6
9	The precise long-term outcomes of adult IgA nephropathy by mail questionnaires: Better renal survival compared to earlier cohort studies. <i>PLoS ONE</i> , 2020, 15, e0233186.	2.5	4
10	VI. IgA Nephropathy. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 917-925.	0.0	0
11	Association Between Tonsillectomy and Outcomes in Patients With Immunoglobulin A Nephropathy. <i>JAMA Network Open</i> , 2019, 2, e194772.	5.9	59
12	Plasma Exchange Is Highly Effective for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Patients With Rapidly Progressive Glomerulonephritis Who Have Advanced to Dialysis Dependence: A Single-Center Case Series. <i>Therapeutic Apheresis and Dialysis</i> , 2019, 23, 253-260.	0.9	1
13	A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 16-25.	1.6	18
14	Maintenance treatment using the purine-synthesis inhibitor mizoribine in a patient with relapsing thrombotic thrombocytopenic purpura. <i>CEN Case Reports</i> , 2018, 7, 24-28.	0.9	2
15	Reproducibility for pathological prognostic parameters of the Oxford classification of IgA nephropathy: a Japanese cohort study of the Ministry of Health, Labor and Welfare. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 92-96.	1.6	20
16	Reproducibility for pathological prognostic parameters of the Oxford classification of IgA nephropathy: the authors reply. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 1137-1138.	1.6	2
17	Anaemia is an essential complication of ANCA-associated renal vasculitis: a single center cohort study. <i>BMC Nephrology</i> , 2017, 18, 337.	1.8	21
18	Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan. <i>CEN Case Reports</i> , 2016, 5, 87-90.	0.9	2

#	ARTICLE	IF	CITATIONS
19	Reduction of proteinuria by therapeutic intervention improves the renal outcome of elderly patients with IgA nephropathy. <i>Clinical and Experimental Nephrology</i> , 2016, 20, 910-917.	1.6	10
20	Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy. <i>Clinical and Experimental Nephrology</i> , 2016, 20, 244-252.	1.6	12
21	Tonsillectomy reduces recurrence of IgA nephropathy in mesangial hypercellularity type categorized by the Oxford classification. <i>Clinical and Experimental Nephrology</i> , 2016, 20, 425-432.	1.6	17
22	Clinicopathological characteristics of patients with immunoglobulin A nephropathy showing acute exacerbations after favorable long-term clinical courses. <i>Clinical and Experimental Nephrology</i> , 2016, 20, 226-234.	1.6	2
23	Is Tonsillectomy a Possible Treatment for IgA Nephropathy from Randomized Controlled Trial (RCT)?., 2016, , 321-330.		0
24	Ambulatory blood pressure and tubulointerstitial injury in patients with IgA nephropathy. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 716-721.	2.9	4
25	Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study. <i>Clinical and Experimental Nephrology</i> , 2015, 19, 925-932.	1.6	6
26	A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1546-1553.	0.7	149
27	The role of a low glomerular density and being overweight in the etiology of proteinuria in CKD patients without known glomerular diseases. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 911-917.	1.6	4
28	Overestimation of the risk of progression to end-stage renal disease in the poor prognosis group according to the 2002 Japanese histological classification for immunoglobulin A nephropathy. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 475-480.	1.6	1
29	The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 555-562.	1.6	24
30	Nationwide survey on current treatments for IgA nephropathy in Japan. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 827-833.	1.6	48
31	Primary membranoproliferative glomerulonephritis on the decline: decreased rate from the 1970s to the 2000s in Japan. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 248-254.	1.6	11
32	A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. <i>Journal of Nephrology</i> , 2013, 26, 350-357.	2.0	88
33	Low Glomerular Density with Glomerulomegaly in Obesity-Related Glomerulopathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 735-741.	4.5	97
34	A Predictive Clinical Grading System for Immunoglobulin A Nephropathy by Combining Proteinuria and Estimated Glomerular Filtration Rate. <i>Nephron Clinical Practice</i> , 2011, 118, c292-c300.	2.3	15
35	The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. <i>Kidney International</i> , 2009, 76, 546-556.	5.2	892
36	Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. <i>Clinical and Experimental Nephrology</i> , 2009, 13, 460-466.	1.6	68

#	ARTICLE	IF	CITATIONS
37	The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. <i>Kidney International</i> , 2009, 76, 534-545.	5.2	1,028
38	Treatment of IgA Nephropathy: Corticosteroids, Tonsillectomy, and Mycophenolate Mofetil. , 2007, 157, 37-43.		9
39	Prospective trial of combined therapy with heparin?warfarin and renin?angiotensin system (RAS) inhibitors in progressive IgA nephropathy (IgAN). <i>Nephrology</i> , 2006, 11, A66-A66.	1.6	0
40	Role of obesity-related factors in development of IgA nephropathy. <i>Nephrology</i> , 2006, 11, A70-A70.	1.6	0
41	Role of lymphangiogenesis for long-term renal survival in advanced IgA nephropathy. <i>Nephrology</i> , 2005, 10, A438-A438.	1.6	0
42	A role of BMP in the development of glomerular sclerosis. <i>Nephrology</i> , 2005, 10, A444-A444.	1.6	1
43	Prognostic impact of widened peritubular capillaries associated with compensatory tubular hypertrophy in advanced IgA nephropathy. <i>Nephrology</i> , 2004, 9, A52-A52.	1.6	0
44	Glomerular remodeling by bone marrow-derived cells after bone marrow transplantation should attenuate murine IgA nephropathy. <i>Nephrology</i> , 2003, 8, A95-A96.	1.6	0
45	Remodeling of renal microvasculature is strongly associated with long-term prognosis of advanced IgA nephropathy. <i>Nephrology</i> , 2003, 8, A120-A120.	1.6	0
46	Serum cystatin C may predict the prognostic stages of patients with IgA nephropathy prior to renal biopsy. <i>Journal of Clinical Laboratory Analysis</i> , 2001, 15, 25-29.	2.1	18
47	Inflamed Glomeruli? Specific Gene Activation that Uses Recombinant Adenovirus with the Cre/loxP System. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2330-2337.	6.1	12
48	The Potential of Bone Marrow-Derived Cells to Differentiate to Glomerular Mesangial Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1401-1409.	6.1	192
49	Measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy. <i>Journal of Clinical Laboratory Analysis</i> , 2000, 14, 220-223.	2.1	51
50	Measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy. , 2000, 14, 220.		2
51	Polymorphism of renin-angiotensin system genes in progressive IgA nephropathy. <i>Nephrology</i> , 1997, 3, s719-s723.	1.6	3
52	Bacterial superantigen enhances cytokine production by T-helper lymphocyte subset-2 cells and modifies glomerular lesions in experimental immunoglobulin a nephropathy. <i>Clinical and Experimental Nephrology</i> , 1997, 1, 83-91.	1.6	1
53	Rhabdomyolysis Associated with Bacteremia due to <i>Streptococcus viridans</i> .. <i>Internal Medicine</i> , 1995, 34, 785-789.	0.7	6
54	Effects of antihypertensive drugs on glomerular morphology. <i>Kidney International</i> , 1989, 36, 626-635.	5.2	213